Clinical value of EMP chemotherapy program in the treatment of gestational tophoblastic neoplasia

Objective: To discuss the clinical value of EMP(etoposide,methotrexate and platinum) chemotherapy in the treatment of gestational tophoblastic neoplasia(GTN). Methods: Twenty-two cases with GTN were treated with EMP program(including 6 cases treated with simple EMP program and EMP program as for second-line treatment in 16 cases).MTX as the initial chemotherapy in 7 cases(31.8%),FAV as the initial chemotherapy in 8 cases(18.2%),FAVE as the initial chemotherapy in 4 cases(18.2%),EMA-Co as the initial chemotherapy in 2 cases(9.1%) and VMP as the initial chemotherapy in 1 case(4.5%) were implemented.One cases were operated based on chemotherapy. Results: The serology index of all patients arrived at the complete alleviation,the alleviation rate of which was 100%(the simple program for 37.5%).The bone marrow suppression,digestive tract reaction,hair loss and slight hepatic and renal toxicity were the major adverse reactions,the difference of which was statistical significance(P<0.05).The IV degree neutropenia and Ⅲ degree thrombocytopenia in 1 case at three course of chemotherapy alleviated after the treatment with colony stimulating factor(CSF) and recombinant human interleukin-11.Twenty-two patients were followed up,the unintended pregnancy in 1 case after 2 months of chemotherapy was identified,who recovered normal after the abortion,and other cases were normal. Conclusions: The initial or second-line chemotherapy with EMP in the treatment of GTN is good effect,which is worthy of promotion.